BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 28280736)

  • 1. MicroRNA-Related Polymorphisms in PI3K/Akt/mTOR Pathway Genes Are Predictive of Limited-Disease Small Cell Lung Cancer Treatment Outcomes.
    Jiang W; Zhang W; Wu L; Liu L; Men Y; Wang J; Liang J; Hui Z; Zhou Z; Bi N; Wang L
    Biomed Res Int; 2017; 2017():6501385. PubMed ID: 28280736
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MicroRNA-related polymorphisms in apoptosis pathway genes are predictive of clinical outcome in patients with limited disease small cell lung cancer.
    Jiang W; Bi N; Zhang WJ; Wu LH; Liu LP; Men Y; Wang JB; Liang J; Hui ZG; Zhou ZM; Wang LH
    Oncotarget; 2016 Apr; 7(16):22632-8. PubMed ID: 26988918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
    Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
    BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic profiling-based prognostic prediction of patients with advanced small-cell lung cancer in large scale analysis.
    Udagawa H; Umemura S; Murakami I; Mimaki S; Makinoshima H; Ishii G; Miyoshi T; Kirita K; Matsumoto S; Yoh K; Niho S; Tsuchihara K; Goto K
    Lung Cancer; 2018 Dec; 126():182-188. PubMed ID: 30527185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic variations in the PI3K-PTEN-AKT-mTOR pathway are associated with distant metastasis in nasopharyngeal carcinoma patients treated with intensity-modulated radiation therapy.
    Guo Q; Lu T; Chen Y; Su Y; Zheng Y; Chen Z; Chen C; Lin S; Pan J; Yuan X
    Sci Rep; 2016 Nov; 6():37576. PubMed ID: 27876891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy.
    Tsurutani J; West KA; Sayyah J; Gills JJ; Dennis PA
    Cancer Res; 2005 Sep; 65(18):8423-32. PubMed ID: 16166321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic variations of the PI3K-AKT-mTOR pathway and clinical outcome in muscle invasive and metastatic bladder cancer patients.
    Chen M; Gu J; Delclos GL; Killary AM; Fan Z; Hildebrandt MA; Chamberlain RM; Grossman HB; Dinney CP; Wu X
    Carcinogenesis; 2010 Aug; 31(8):1387-91. PubMed ID: 20530239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features.
    Trigka EA; Levidou G; Saetta AA; Chatziandreou I; Tomos P; Thalassinos N; Anastasiou N; Spartalis E; Kavantzas N; Patsouris E; Korkolopoulou P
    Oncol Rep; 2013 Aug; 30(2):623-36. PubMed ID: 23728071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical significance of genetic variations in the PI3K/PTEN/AKT/mTOR pathway in Korean patients with colorectal cancer.
    Kim JG; Chae YS; Sohn SK; Kang BW; Moon JH; Lee SJ; Jeon SW; Park JS; Park JY; Choi GS
    Oncology; 2010; 79(3-4):278-82. PubMed ID: 21412012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of PI3K/AKT Pathway Is a Potential Mechanism of Treatment Resistance in Small Cell Lung Cancer.
    Jin Y; Chen Y; Tang H; Hu X; Hubert SM; Li Q; Su D; Xu H; Fan Y; Yu X; Chen Q; Liu J; Hong W; Xu Y; Deng H; Zhu D; Li P; Gong Y; Xia X; Gay CM; Zhang J; Chen M
    Clin Cancer Res; 2022 Feb; 28(3):526-539. PubMed ID: 34921019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic priority of the PI3K/AKT/mTOR pathway in small cell lung cancers as revealed by a comprehensive genomic analysis.
    Umemura S; Mimaki S; Makinoshima H; Tada S; Ishii G; Ohmatsu H; Niho S; Yoh K; Matsumoto S; Takahashi A; Morise M; Nakamura Y; Ochiai A; Nagai K; Iwakawa R; Kohno T; Yokota J; Ohe Y; Esumi H; Tsuchihara K; Goto K
    J Thorac Oncol; 2014 Sep; 9(9):1324-31. PubMed ID: 25122428
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Associations between single-nucleotide polymorphisms in the PI3K-PTEN-AKT-mTOR pathway and increased risk of brain metastasis in patients with non-small cell lung cancer.
    Li Q; Yang J; Yu Q; Wu H; Liu B; Xiong H; Hu G; Zhao J; Yuan X; Liao Z
    Clin Cancer Res; 2013 Nov; 19(22):6252-60. PubMed ID: 24077347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. miR-218 inhibits the invasion and migration of colon cancer cells by targeting the PI3K/Akt/mTOR signaling pathway.
    Zhang X; Shi H; Tang H; Fang Z; Wang J; Cui S
    Int J Mol Med; 2015 May; 35(5):1301-8. PubMed ID: 25760926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MiR-206 inhibits HGF-induced epithelial-mesenchymal transition and angiogenesis in non-small cell lung cancer via c-Met /PI3k/Akt/mTOR pathway.
    Chen QY; Jiao DM; Wu YQ; Chen J; Wang J; Tang XL; Mou H; Hu HZ; Song J; Yan J; Wu LJ; Chen J; Wang Z
    Oncotarget; 2016 Apr; 7(14):18247-61. PubMed ID: 26919096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of MTOR and AKT Gene Polymorphisms with Susceptibility and Survival of Gastric Cancer.
    Piao Y; Li Y; Xu Q; Liu JW; Xing CZ; Xie XD; Yuan Y
    PLoS One; 2015; 10(8):e0136447. PubMed ID: 26317520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EPHA3 regulates the multidrug resistance of small cell lung cancer via the PI3K/BMX/STAT3 signaling pathway.
    Peng J; Wang Q; Liu H; Ye M; Wu X; Guo L
    Tumour Biol; 2016 Sep; 37(9):11959-11971. PubMed ID: 27101199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic Determinants of Sensitivity to Phosphatidylinositol 3-Kinase Pathway Inhibitor in Small-Cell Lung Carcinoma.
    Makinoshima H; Umemura S; Suzuki A; Nakanishi H; Maruyama A; Udagawa H; Mimaki S; Matsumoto S; Niho S; Ishii G; Tsuboi M; Ochiai A; Esumi H; Sasaki T; Goto K; Tsuchihara K
    Cancer Res; 2018 May; 78(9):2179-2190. PubMed ID: 29490947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway: an emerging treatment strategy for squamous cell lung carcinoma.
    Beck JT; Ismail A; Tolomeo C
    Cancer Treat Rev; 2014 Sep; 40(8):980-9. PubMed ID: 25037117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor invasion and metastasis regulated by microRNA-184 and microRNA-574-5p in small-cell lung cancer.
    Zhou R; Zhou X; Yin Z; Guo J; Hu T; Jiang S; Liu L; Dong X; Zhang S; Wu G
    Oncotarget; 2015 Dec; 6(42):44609-22. PubMed ID: 26587830
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dysregulated PI3K/Akt/PTEN pathway is a marker of a short disease-free survival in node-negative breast carcinoma.
    Capodanno A; Camerini A; Orlandini C; Baldini E; Resta ML; Bevilacqua G; Collecchi P
    Hum Pathol; 2009 Oct; 40(10):1408-17. PubMed ID: 19428048
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.